Back to Top

Clinical Cancer Research (CCR)

Publisher :

American Association for Cancer Research (AACR)

Scopus Profile
Peer reviewed only
Scopus Profile
Open Access
  • pharmacology
  • animal studies
  • Cancer
  • +1

e-ISSN :

1557-3265

Issue Frequency :

Bi-Weekly

p-ISSN :

1078-0432

Est. Year :

1995

Mobile :

2154409300

Country :

United States

Language :

English

APC :

YES

Impact Factor Assignee :

Google Scholar

Email :

pubsales@aacr.org

Journal Descriptions

Clinical Cancer Research publishes innovative clinical and translational cancer research studies that bridge the laboratory and the clinic. The Journal is especially interested in clinical trials evaluating new treatments, accompanied by research on pharmacology, and molecular alterations or biomarkers that predict response or resistance to treatment. The Journal also prioritizes laboratory and animal studies of new drugs and molecule-targeted agents with the potential to lead to clinical trials, and studies of targetable mechanisms of oncogenesis, progression of the malignant phenotype, and metastatic disease. Specific areas of interest include clinical and translational research in targeted therapies; mechanisms of drug sensitivity and resistance; pharmacogenetics and pharmacogenomics; personalized medicine; novel applications of bioinformatics and biostatistics; immunotherapy and clinical immunology; gene therapy; radiobiology and radiation oncology; large-scale molecular characterization of human tumors; diagnostic biomarkers; innovative imaging and other novel methods with potential applicability to clinical investigation; clinical genetics; and detection of minimal disease.


Clinical Cancer Research (CCR) is :

International, Peer-Reviewed, Open Access, Refereed, pharmacology, animal studies, Cancer, drug sensitivity , Online or Print, Bi-Weekly Journal

UGC Approved, ISSN Approved: P-ISSN - 1078-0432, E-ISSN - 1557-3265, Established in - 1995, Impact Factor

Not Provide Crossref DOI

Indexed in Scopus, WoS, PubMed

Not indexed in DOAJ, UGC CARE

Publications of CCR

Research Article
  • dott image Luc Friboulet
  • dott image January, 2020

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

Purpose: Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor with proven efficacy in patients with ALK-rearranged lung cancer previously treated with...

Establish Your Own Journal Without the Expense!

OJSCloud offers a complete, free setup to get you publishing.

Start Your Free Journal!
free profile